Hims & Hers Health (NYSE:HIMS) Earns Hold Rating from Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Hims & Hers Health (NYSE:HIMS) in a report released on Tuesday morning, Marketbeat.com reports. Jefferies Financial Group currently has a $15.00 target price on the stock, down from their prior target price of $17.00.

HIMS has been the topic of a number of other reports. TheStreet raised shares of Hims & Hers Health from a d rating to a c rating in a research report on Monday, March 4th. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a neutral rating in a research report on Tuesday, February 27th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a hold rating in a research report on Tuesday, February 27th. Tigress Financial lifted their price objective on shares of Hims & Hers Health from $14.00 to $15.00 and gave the stock a buy rating in a research report on Friday, January 5th. Finally, Leerink Partnrs reaffirmed a market perform rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $14.85.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $12.69 on Tuesday. The stock has a market capitalization of $2.72 billion, a P/E ratio of -115.36 and a beta of 0.91. The company has a 50-day moving average price of $13.36 and a 200-day moving average price of $9.77. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. During the same period last year, the company earned ($0.05) earnings per share. The business’s revenue was up 47.4% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.1 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 22,839 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17. Following the completion of the transaction, the insider now owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 15,100 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $9.01, for a total value of $136,051.00. Following the completion of the transaction, the chief executive officer now owns 51,653 shares of the company’s stock, valued at approximately $465,393.53. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 22,839 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17. Following the completion of the transaction, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. Insiders have sold a total of 673,335 shares of company stock valued at $8,452,208 over the last quarter. Company insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Graham Capital Management L.P. boosted its stake in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after purchasing an additional 96,277 shares in the last quarter. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 9.2% in the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after purchasing an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after purchasing an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $1,596,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.